There was a positive flow of capital into the biotech sector during the third quarter.BB Biotech is actively increasing its exposure to new drug development technology such as RNA-based therapeutic agents, and gene and cell-based therapies.
2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and our holdings in focus. We continue to expect new product launches and their uptake in the market to accelerate the already positive underlying growth in revenues and cash flows experienced…
With a total return of 23.1% in CHF BB Biotech delivered a strong performance in 2017. A record regular dividend of CHF 3.30 per share will be proposed at the AGM.
Major headwinds caused by various factors weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech was not completely immune to these developments and delivered a return of 1.2% in EUR.
Big players in the healthcare sector are desperate to differentiate their approved ‘checkpoint inhibitors’ (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs. Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in…
Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors.
Biotech companies are increasingly pioneering groundbreaking therapies for diseases with high-unmet medical need. Investing in these innovation leaders is a hallmark of BB Biotech’s investment philosophy.
